Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Norepinephrine in Acute Perforating Artery Stroke
NCT06059144Phase 3Recruiting
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Nov 2024
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of norepinephrine in ischemic stroke (2 arms), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: modified Rankin Scale at Day 90. Started Nov 2024; status: recruiting.
02
Drugs
norepinephrine
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06059144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06059144.